Hepatocellular Carcinoma
📧 Sign up to get email alerts when something new happens for Hepatocellular Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-12-29Clinical Trial Update: Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) [Phase 2]
Phase 2 randomized, double-blind trial of CF102 in hepatocellular carcinoma completed with results posted.
-
FDA label_change · 2021-12-28FDA Approved: EOVIST — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for EOVIST (gadoxetate disodium) to update the product labeling.
-
CLINICAL_TRIALS trial_result · 2021-12-28Clinical Trial Update: Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC [Phase 2]
A Phase 2 trial evaluating camrelizumab in combination with apatinib and NK cells for advanced hepatocellular carcinoma is ongoing, with sta…
-
CLINICAL_TRIALS trial_result · 2021-12-27Clinical Trial Update: Association of Conformational High-dose Radiotherapy and of Hyperselective Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma [Phase 2]
Phase 2 trial update evaluating high-dose conformational radiotherapy and hyperselective transarterial chemoembolization for hepatocellular …
-
CLINICAL_TRIALS trial_result · 2021-12-22Clinical Trial Update: Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma [Phase 2]
Phase 2 clinical trial evaluating donafenib combined with sintilimab and hepatic artery infusion chemotherapy as first-line treatment for un…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-12-17Clinical Trial Update: Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma [Phase 2]
Phase 2 clinical trial update evaluating donafenib combined with TACE as adjuvant therapy for hepatocellular carcinoma.
-
CLINICAL_TRIALS trial_result · 2021-12-06Clinical Trial Update: A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma [Phase 2]
Phase 2 trial update assessing durvalumab and tremelimumab as monotherapy or in combination (durvalumab plus tremelimumab) or with bevacizum…
-
CLINICAL_TRIALS trial_result · 2021-12-06Clinical Trial Update: Trial Comparing PLA to HIGRT (PROVE-HCC) [NA]
A terminated clinical trial (PROVE-HCC) comparing PLA to HIGRT in hepatocellular carcinoma with results posted.
-
CLINICAL_TRIALS trial_result · 2021-12-02Clinical Trial Update: SBRT or TACE for Advanced HCC [Phase 3]
Phase 3 trial update comparing SBRT versus TACE for advanced hepatocellular carcinoma is ongoing with unknown status.
-
CLINICAL_TRIALS trial_result · 2021-11-30Clinical Trial Update: HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer [Phase 3]
A Phase 3 trial evaluating HepaSphere/Quadrasphere microspheres delivering doxorubicin for hepatocellular carcinoma was terminated with resu…
-
CLINICAL_TRIALS trial_result · 2021-11-26Clinical Trial Update: HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure [Phase 2]
Phase 2 trial evaluating hepatic arterial infusion chemotherapy (HAIC) combined with camrelizumab and tyrosine kinase inhibitor (TKI) for un…
-
CLINICAL_TRIALS trial_result · 2021-11-24Clinical Trial Update: A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC) [Phase 2]
Phase II single-arm study evaluating toripalimab with bevacizumab as first-line therapy for advanced hepatocellular carcinoma.
-
CLINICAL_TRIALS trial_result · 2021-11-19Clinical Trial Update: A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC) [Phase 1, Phase 2]
Clinical trial evaluating the safety and efficacy of combining Pexa-Vec with nivolumab in first-line advanced hepatocellular carcinoma; the …
-
CLINICAL_TRIALS trial_result · 2021-11-05Clinical Trial Update: A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma [Phase 3]
Phase 3 trial comparing atezolizumab with bevacizumab versus sorafenib in untreated locally advanced or metastatic hepatocellular carcinoma …
-
CLINICAL_TRIALS trial_result · 2021-11-05Clinical Trial Update: Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation [Phase 3]
Phase 3 clinical trial evaluating neo-adjuvant transarterial chemoinfusion for hepatocellular carcinoma patients beyond Milan/UCSF criteria …
-
CLINICAL_TRIALS trial_result · 2021-10-22Clinical Trial Update: The Clinical Validity and Safety of IOP Injection MRI Contrast Agent in Hepatocellular Carcinoma [Phase 2]
Phase 2 clinical trial evaluating the validity and safety of an MRI contrast agent injected intraocularly? (IOP) for hepatocellular carcinom…
-
CLINICAL_TRIALS trial_result · 2021-10-12Clinical Trial Update: Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma [Phase 2]
Phase 2 study of milciclib in unresectable/metastatic hepatocellular carcinoma completed.
-
CLINICAL_TRIALS trial_result · 2021-10-06Clinical Trial Update: Stereotactic Body Radiation Therapy (SBRT) Hepatocellular Carcinoma (COLD 2) [Phase 2]
Phase 2 trial update for stereotactic body radiation therapy in hepatocellular carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2021-10-06Clinical Trial Update: Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis [Phase 2]
A Phase 2 proof-of-concept study evaluating the efficacy of P03277 MR imaging for diagnosing hepatocellular carcinoma.
-
CLINICAL_TRIALS trial_result · 2021-09-28Clinical Trial Update: TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Hepatocellular Carcinoma (BCLC-C Stage ): a Prospective Single-arm Phase II Clinical Study [Phase 2]
Phase II single-arm trial evaluating TACE combined with sintilimab and a bevacizumab biosimilar in hepatocellular carcinoma (BCLC-C).
-
CLINICAL_TRIALS trial_result · 2021-09-24Clinical Trial Update: Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC [Phase 3]
Phase 3 trial evaluating toripalimab in combination with lenvatinib and TACE as conversion therapy for potentially resectable hepatocellular…
-
CLINICAL_TRIALS trial_result · 2021-09-24Clinical Trial Update: TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma [Phase 2]
Phase 2 clinical trial update evaluating the combination of transarterial chemoembolization (TACE) with lenvatinib for unresectable hepatoce…
-
CLINICAL_TRIALS trial_result · 2021-09-22Clinical Trial Update: PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial [Phase 2]
A single-arm Phase 2 clinical trial evaluating PD-1 antibody plus lenvatinib and TACE-HAIC for potentially resectable hepatocellular carcino…
-
CLINICAL_TRIALS trial_result · 2021-09-22Clinical Trial Update: Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria [NA]
A terminated clinical trial comparing proton radiotherapy plus sorafenib to sorafenib alone for hepatocellular carcinoma beyond the San Fran…
-
CLINICAL_TRIALS trial_result · 2021-09-21Clinical Trial Update: Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis [Phase 4]
Phase 4 clinical trial evaluating radiotherapy plus donafenib as neoadjuvant therapy for hepatocellular carcinoma with portal vein tumor thr…